Similar articles for PMID: 34272317

Year	Number of Results
1999	1
2002	1
2004	1
2005	1
2007	4
2008	1
2009	1
2010	2
2011	2
2012	3
2013	7
2014	8
2015	6
2016	12
2017	15
2018	14
2019	12
2020	15
2021	14
2022	5
2023	2
2024	0

1

18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma.

Benz MR, Armstrong WR, Ceci F, Polverari G, Donahue TR, Wainberg ZA, Quon A, Auerbach M, Girgis MD, Herrmann K, Czernin J, Calais J. Benz MR, et al. J Nucl Med. 2022 Feb;63(2):199-204. doi: 10.2967/jnumed.121.261952. Epub 2021 Jul 16. J Nucl Med. 2022. PMID: 34272317 Free article.

2

Prospective comparison of early interim ¹⁸F-FDG-PET with ¹⁸F-FLT-PET for predicting treatment response and survival in metastatic breast cancer.

Su TP, Huang JS, Chang PH, Lui KW, Hsieh JC, Ng SH, Chan SC. Su TP, et al. BMC Cancer. 2021 Aug 10;21(1):908. doi: 10.1186/s12885-021-08649-z. BMC Cancer. 2021. PMID: 34376155 Free PMC article.

3

The predictive value of ¹⁸F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy.

Mattoli MV, Massaccesi M, Castelluccia A, Scolozzi V, Mantini G, Calcagni ML. Mattoli MV, et al. Radiat Oncol. 2017 Jan 5;12(1):4. doi: 10.1186/s13014-016-0737-0. Radiat Oncol. 2017. PMID: 28057034 Free PMC article.

4

Response Monitoring in Metastatic Breast Cancer: A Prospective Study Comparing ¹⁸F-FDG PET/CT with Conventional CT.

Vogsen M, Harbo F, Jakobsen NM, Nissen HJ, Dahlsgaard-Wallenius SE, Gerke O, Jensen JD, Asmussen JT, Jylling AMB, Braad PE, Vach W, Ewertz M, Hildebrandt MG. Vogsen M, et al. J Nucl Med. 2023 Mar;64(3):355-361. doi: 10.2967/jnumed.121.263358. Epub 2022 Oct 7. J Nucl Med. 2023. PMID: 36207136 Free PMC article.

5

Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).

Fledelius J, Khalil AA, Hjorthaug K, Frøkiaer J. Fledelius J, et al. J Med Imaging Radiat Oncol. 2016 Apr;60(2):231-8. doi: 10.1111/1754-9485.12427. Epub 2015 Dec 18. J Med Imaging Radiat Oncol. 2016. PMID: 26678718

6

Predicting tumor response and outcome of second-look surgery with ¹⁸F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer.

Aide N, Fauchille P, Coquan E, Ferron G, Combe P, Meunier J, Alexandre J, Berton D, Leary A, De Rauglaudre G, Bonichon N, Pujade Lauraine E, Joly F. Aide N, et al. Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1998-2008. doi: 10.1007/s00259-020-05092-3. Epub 2020 Nov 21. Eur J Nucl Med Mol Imaging. 2021. PMID: 33221969 Free PMC article.

7

18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation.

Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL. Cashen AF, et al. J Nucl Med. 2011 Mar;52(3):386-92. doi: 10.2967/jnumed.110.082586. Epub 2011 Feb 14. J Nucl Med. 2011. PMID: 21321279 Free PMC article.

8

Interim [¹⁸F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma.

Sachpekidis C, Kopp-Schneider A, Pan L, Papamichail D, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A. Sachpekidis C, et al. Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1932-1943. doi: 10.1007/s00259-020-05137-7. Epub 2020 Dec 18. Eur J Nucl Med Mol Imaging. 2021. PMID: 33336264 Free PMC article.

9

¹⁸F-FDG PET/CT Is an Early Predictor of Pathologic Tumor Response and Survival After Preoperative Radiochemotherapy with Bevacizumab in High-Risk Locally Advanced Rectal Cancer.

Avallone A, Aloj L, Pecori B, Caracò C, De Stefano A, Tatangelo F, Silvestro L, Granata V, Bianco F, Romano C, Di Gennaro F, Budillon A, Petrillo A, Muto P, Botti G, Delrio P, Lastoria S. Avallone A, et al. J Nucl Med. 2019 Nov;60(11):1560-1568. doi: 10.2967/jnumed.118.222604. Epub 2019 Mar 15. J Nucl Med. 2019. PMID: 30877175 Free PMC article. Clinical Trial.

10

The utility of ⁶⁸F-FDG PET/CT for evaluation of tumor response to immune checkpoint inhibitor therapy and prognosis prediction in patients with non-small-cell lung cancer.

Kitajima K, Kawanaka Y, Komoto H, Minami T, Yokoi T, Kuribayashi K, Kijima T, Nakamura A, Hashimoto M, Kondo N, Hasegawa S, Yamakado K. Kitajima K, et al. Hell J Nucl Med. 2021 Sep-Dec;24(3):186-198. doi: 10.1967/s002449912402. Epub 2021 Dec 17. Hell J Nucl Med. 2021. PMID: 34901959 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

102 results

Results by year